Decisions about the role of adjuvant therapy in the management of colorectal cancer are rarely taken on the basis of sound scientific evidence. This is not because surgeons are capricious, but because sound scientific evidence is, unfortunately, a little thin on the ground. Since the first randomised trial in the UK was initiated some 15 years ago, less than 1% of the 26,000 cases of colorectal cancer each year have been entered into randomised clinical trials and a similar situation exists elsewhere. A recent overview of all of the published evidence worldwide from trials of radiotherapy in rectal cancer identified trials involving in total only some 5,000 patients. The individual trials were all too small to detect reliably (or refute reliably) any realistically moderate improvement in survival and, even when combined, their results are equivocal (Buyse et al., 1988) . It is thus hardly surprising that surgeons are divided in their views of whether or not radiotherapy is a useful adjuvant treatment in this disease. A similar situation exists when considering the role of chemotherapy where, again, there is considerable uncertainty about whether adjuvant chemotherapy has any effect on mortality at all and, if it does have an effect, no consensus about the likely size of that effect. Recently, however, evidence that chemotherapy -usually with 5-fluorouracil (5-FU) containing regimens -can moderately improve survival has been accumulating. The most promising treatments that have been examined are a 1-week post-operative infusion of 5-FU through the portal vein (Taylor et al., 1985) , 18 months systemic administration of MOF Wolmark et al., 1988 ) and a year of systemic 5-FU given in conjunction with levamisole (Moertel et al., 1990) . There is clearly a need for a more precise definition of the effect of adjuvant therapy on long term survival and so, in November 1989, the UKCCCR launched AXIS, an international randomised trial designed to be large enough to get definite evidence about any survival benefit of intraportal 5-FU and of perioperative radiotherapy. Even a moderate improvement in survival in this disease would be important because, since colorectal cancer is so common, an improvement of 'only' 5% in 5-year survival (say from 50% to 55%) could save many thousands of lives each year.
Perioperative radiotherapy
The primary treatment for colorectal cancer is -and will remain -radical surgery, which is possible in as many as 70-80% of (Early Breast Cancer Trialists' Collaborative Group, 1988 and was used by Buyse to combine the randomised evidence from published colorectal cancer trials (Buyse et al., 1988) . Since that overview, some more data have become available and an update of the Buyse overview (Figure 1 ) suggests that radiotherapy may reduce mortality by about 10%. However, this difference is of marginal statistical significance and the data are compatible with radiotherapy having no material effect on survival or, alternatively, reducing mortality by as much as 20%. A 10 or 20% mortality reduction would represent a considerable saving in lives given the high incidence of the disease (10,000 cases of rectal cancer/year in the UK alone).
Systemic chemotherapy
Adjuvant systemic chemotherapy has been studied in more than 20 randomised trials and, again, an overview of the available data from randomised trials suggests that adjuvant chemotherapy may reduce mortality by about 10 or 15% (Figure 2 ). Most of the regimens studied included 5-FU, either alone or in combination with other agents. As with the radiotherapy overview, the confidence limits range from almost no difference to a 20% reduction in the odds of death. Even when the data are combined in this way, there remains some uncertainty about whether systemic chemotherapy really does have any effect on long-term mortality and, if so, about the size of the effect. Stockholm (Stockholm Rectal Cancer Group, 1987) , Northwest (North West of England Rectal Cancer Group, 1989) and NSABP R-01 . The data shown in Figure 2 are compatible with all of the chemotherapy regimens having broadly similar effectiveness although, of course, some could well be more effective than others. Because the evidence for a survival benefit of chemotherapy only just reaches the conventional level of significance, there are considerable statistical problems in identifying which, if any, of the several chemotherapy regimens studied is the most effective. For example, even the very striking reduction in mortality of almost a third seen in the recent intergroup trial of 5-FU and levamisole (Moertel et al., 1990 ) is statistically compatible with the overall 14% reduction in the odds of death seen when all the systemic chemotherapy trials are combined (dotted line in Figure 2) . It is therefore possible that a moderate effect of 5-FU may have been inflated by the play of chance in this study. The addition of levamisole to 5-FU does not improve the response rate in advanced colorectal cancer (Buroker et al., 1985) (Moertel et al., 1990) and NSABP R-01 and NSABP C-01 . bSee footnote to Figure 1 . COnly deaths due to colorectal cancer published. advantages over systemic chemotherapy: it involves the surgeon in very little extra work, the cytotoxic course is short (just one week), it has relatively few side-effects, and does not need the patient to be referred to a specialist medical oncologist. The first randomised trial of this treatment reported a highly significant improvement in survival (Taylor et al., 1985) . The authors concluded that further studies were needed to confirm this benefit, and at least eight subsequent studies have been undertaken. The available data (including crude estimates where full data have not been published) were summarised in the AXIS protocol (1989) . Since then, further encouraging results from a large NSABP study and from a Dutch study (Wereldsma et al., 1990 ) have been published. The current evidence from portal vein infusion trials -including estimates where full data are not available -is shown in Figure 3 . Although the subsequent trials have failed to confirm the size of the mortality reduction reported by Taylor et al. (1985) , they do suggest that a short infusion through the portal vein could well confer a survival benefit at least as great as prolonged systemic chemotherapy. However, this overview must be treated with some caution because the data are not firm, the proportion of patients excluded after randomisation in some studies is unusually high, some studies have shown reductions in liver metastases while others have not and there are conflicting results on the stage and site of tumour most likely to benefit. Nevertheless, there can be no doubt about the considerable promise of this relatively simple adjuvant treatment.
AXIS -a large simple trial These overview analyses of radiotherapy and portal vein infusion of 5-FU present clinicians with a real challenge. If these treatments really do improve survival, even moderately, a considerable number of lives can be saved each year. But, in order to be certain about the effect, the treatments need to be studied in thousands rather than in hundreds of patients. On the current evidence, portal vein infusion of appears to be at least as effective as systemic 5-FU and levamisole -and is arguably more promising. Moreover, the human and economic advantages of a treatment that is completed in I week with minimal morbidity are considerable. It is clear that a really large trial that will provide a definite answer is warranted but previous experience shows that cancer treatment trials do not readily accrue such numbers. How can AXIS recruit the substantial numbers of patients needed?
There are three important ways in which AXIS differs from previous colorectal cancer trials. First and foremost, the trial has been designed to be so streamlined that it is practicable for clinicians from hospitals with no resources spare for research to participate. The Second, to accommodate heterogeneous clinical opinion and variable resource availability, considerable flexibility in the treatment schedules is allowed. In particular, radiotherapy can be pre-or post-operative and, provided a reasonably radical dose is used, the fractionation schedule can be according to local practice. Pre-operative radiotherapy delays surgery by some 2 to 6 weeks, but is associated with little morbidity and may allow more limited resections, perhaps reducing the need for colostomies and avoiding some of the urinary and sexual dysfunctions (James et al., 1990) . The morbidity of post-operative radiotherapy is higher because, after surgery, the pelvis often contains small bowel which is rarely irradiated during pre-operative treatment. Post-operative radiotherapy does, however, allow the selection of patients with advanced, but operable tumours and toxicity can be minimised by carefully limiting high radiation doses to the posterior pelvis and by treating patients in the prone position. There is little evidence from previous trials to indicate whether pre-or post-operative treatment is likely to be more effective and so either treatment is allowed.
Finally, eligibility is defined not by the protocol but by the clinician's own judgement -which in itself may be dependent on local factors such as shortage of junior staff or of equipment which are beyond his control. For example, he may be certain about the benefit -or lack of benefit -of radiotherapy in one group of patients, whom he would not randomise, but uncertain in another group whom he would. Or, local constraints on the availability of radiotherapy may mean that he can randomise a patient for intraportal 5-FU, but not for radiotherapy. Or, he may feel that 5-FU is potentially interesting in younger patients, but not for very old patients. Similarly, some surgeons are convinced that portal vein infusion would be an inappropriate treatment for Dukes' A tumours -others are not so sure. Eligibility criteria in AXIS are intentionally loose, so that the clinicians' own uncertainty about what treatment is appropriate for a particular patient is the deciding factor for eligibility. Depending on the view of the participating clinicians a very wide range of patients may be entered. While this might seem to weaken the trial (and it is difficult to persuade many clinicians that it will not) it is, in fact, a positive strength. Given sufficient numbers, a wide range of patients will not only answer whether treatment is of any benefit but also, if it is of benefit, will help identify which type of patient is most likely to benefit.
There is certainly consensus on the need for AXIS. The King's Fund Consensus Conference on Colorectal Cancer 
II
- (BMJ, 1990) held in London recommended that 'surgeons enter suitable patients into the AXIS national trial'. The US National Institutes of Health Consensus meeting (J. Natl Cancer Inst., 1990) concluded that continued clinical trials were essential to define the optimal adjuvant therapy and entry into these trials was 'highly encouraged'. They also recommended that in view of the improved survival results, immediate postoperative chemotherapy needs further investigation. More controversially, they recommended that suitable Stage C colon cancer patients unable to enter a clinical trial should be offered 5-FU and levamisole and that Stage B and C rectal cancer patients should receive combined chemotherapy and radiation therapy. These recommendations have already been widely adopted by US clinicians and the use of adjuvant treatments for colorectal cancer is likely to become more commonplace in the UK also over the next few years. We urgently need AXIS to succeed to get better evidence on the precise role of radiotherapy and on whether portal vein infusion of 5-FU can confer similar -or greater -survival benefits than more prolonged and complex systemic chemotherapy regimens. Clearly this is an important question for UK Surgeons, and already more than 500 patients have been entered.
What are the costs of participating in AXIS? There is almost no extra work involved for collaborating clinicians. The side effects of portal vein infusion of 5-FU are few, and no increase in post-operative mortality has been reported. The costs of not participating could be considerably higher if treatment for colorectal cancer continues to be given on an uninformative ad hoc basis because of a lack of firm evidence about the value of adjuvant therapy.
